Sixty years after Calvin Stevens first synthesized ketamine at Parke-Davis in a pursuit of safer anesthesia, the molecule has completed a remarkable transformation. Once a staple of the operating room, it has emerged as a cornerstone of modern psychiatric intervention. Today, as a potent S-enantiomer nasal spray marketed by Johnson & Johnson as Spravato, the drug is rewriting the standard of care for treatment-resistant depression (TRD).
With recent clinical data presented at Psych Congress Elevate aiming to cement its role in the market, Spravato is poised for significant growth. Following its January 2025 FDA approval as the only monotherapy for TRD, the drug has moved from a niche add-on therapy to a primary focus for clinicians. With annual sales projected to reach $2.3 billion by 2026, the stakes—both financial and clinical—have never been higher.
A Chronology of a Psychiatric Breakthrough
The journey of esketamine from a laboratory curiosity to a multi-billion-dollar therapeutic is marked by distinct regulatory and clinical milestones.
- The Early Days (1960s): Ketamine was synthesized by Calvin Stevens, providing a breakthrough in anesthetic safety. Its unique profile, however, kept it tethered to surgical suites for decades.
- The Paradigm Shift (March 2019): The FDA approved Spravato (esketamine) as a nasal spray for treatment-resistant depression, albeit strictly as an add-on therapy to conventional oral antidepressants.
- The Monotherapy Milestone (January 2025): Regulators cleared a significant hurdle by approving Spravato as the first and only monotherapy for adult patients with TRD. This move removed the requirement for background antidepressant use, significantly expanding the drug’s potential patient population.
- The Current Landscape (2025–2026): After a steady launch phase, Spravato has achieved blockbuster status. With nearly $1.7 billion in sales last year, market analysts expect a trajectory toward $2.3 billion by the end of 2026, fueled by new data focusing on long-term remission.
Defining the Challenge: The Burden of Treatment-Resistant Depression
The clinical necessity for a drug like Spravato is underscored by the staggering statistics surrounding major depressive disorder (MDD). In 2021, an estimated 21 million U.S. adults—roughly 8.3% of the population—experienced at least one major depressive episode. Of the 8.9 million adults receiving pharmacological treatment for MDD, approximately one-third, or 2.8 million individuals, fail to respond to standard oral antidepressants.
This failure to achieve remission is the hallmark of treatment-resistant depression. Dr. Rakesh Jain, MD, MPH, a clinical professor of psychiatry at Texas Tech University School of Medicine, Permian Basin, emphasizes the human cost of this clinical plateau. "There are millions upon millions of patients, some of them your friends and mine, some of them your family members, who are being treated for depression and are simply not in remission," Dr. Jain noted.
The difficulty in achieving remission is often compared to the seminal STARD trial, the largest real-world study of depression treatment. The data from STARD revealed a sobering trend: while roughly 28% of patients achieved remission on their first antidepressant, that figure plummeted to 13.7% by the third treatment step. "The moment you go to a second antidepressant, the remission rate drops sharply," Dr. Jain explained. "It’s a very sharp drop."
The Science of Remission: Analyzing the New Data
The recent presentation at Psych Congress Elevate sought to address the "remission gap" by synthesizing data from six major clinical trials. The core of the analysis utilizes the Montgomery-Åsberg Depression Rating Scale (MADRS), a 60-point clinician-rated instrument. Remission is traditionally defined as a score of 10 or below.
The Methodology
The analysis compiled data from:
- TRD4005: A four-week, placebo-controlled monotherapy trial.
- TRANSFORM-2: A placebo-controlled study pairing esketamine with oral antidepressants.
- ESCAPE-TRD: An active-controlled trial comparing esketamine to quetiapine extended-release.
- Three Open-Label Extensions (ESCAPE-LTE, SUSTAIN-2, SUSTAIN-3): Long-term follow-up studies tracking patients for up to 5.5 years.
Key Findings
The data highlights impressive short-term and long-term results. In TRANSFORM-2, patients on Spravato plus an oral antidepressant achieved a 42.6% remission rate compared to 24% for the placebo-plus-antidepressant group.
Perhaps more compelling are the findings from the open-label extension studies, which tracked patients over several years. Remission rates were reported at 49.3% at one year, 78.2% at approximately 2.5 years, and 43.2% at the 5.5-year mark. While these figures represent a compilation of data rather than a formal meta-analysis, they provide a powerful narrative for clinicians looking for durable, long-term options.
Professional Perspectives and Industry Scrutiny
Despite the enthusiasm surrounding the data, the psychiatric community remains divided. The professional reception of esketamine exists on a spectrum, influenced by both clinical efficacy and systemic barriers.
Official Guidelines and Regulatory Caution
The 2022 VA/DoD clinical practice guidelines offer a "weak for" recommendation for ketamine or esketamine, citing concerns over monitoring requirements and the limited nature of existing evidence. Similarly, the UK’s National Institute for Health and Care Excellence (NICE) declined to recommend routine use of esketamine within the NHS, citing insufficient economic and clinical data to support cost-effectiveness.
Academic Critique
Critics, including researchers like Sanjay Mathew and Nicholas Murphy of Baylor College of Medicine, have questioned the long-term design of the phase 3 programs. In a 2025 editorial in the American Journal of Psychiatry, they argued that the clinical evidence does not definitively support the necessity of long-term maintenance beyond the initial weeks of treatment. A systematic review by Fountoulakis et al. further noted that the effect sizes for add-on therapy are comparable to those of atypical antipsychotic augmentation—a class of drugs often criticized for their own lack of robust efficacy in TRD.
The Human Factor: Overcoming Inertia
Dr. Jain argues that the primary hurdle to widespread adoption is not just the data, but "clinician psychology." Psychiatry, he suggests, is historically slow to adopt new technologies, often preferring the familiarity of traditional oral antidepressants despite their known limitations.
"Psychiatry is slow to change, it just is," Dr. Jain remarked. "There are many clinicians who have heard of Spravato but are hesitant, not for any particular reason; that’s just the nature of our field."
Beyond hesitation, there are tangible logistical burdens. Because of risks associated with sedation, dissociation, and abuse, Spravato is governed by a strict Risk Evaluation and Mitigation Strategy (REMS). This requires the drug to be administered in a certified clinical setting, followed by a mandatory two-hour observation period and a prohibition on driving until the following day. These requirements represent a significant departure from the convenience of daily oral medications.
Implications for the Future of Mental Health
The push by Johnson & Johnson to center "remission" as the primary goal of treatment is a strategic shift in the mental health industry. By focusing on the high-threshold MADRS score of 10 or below, J&J is attempting to redefine success. No longer is "symptom reduction" sufficient; the industry is increasingly focused on "total remission."
For patients, this represents a new horizon. The ability to achieve and maintain remission for years, as suggested by the long-term data presented at Psych Congress Elevate, could change the lives of millions. However, the path forward requires a balance between clinical optimism and scientific rigor.
As the medical community continues to digest the long-term follow-up studies and the comparative data against active treatments like quetiapine, the debate will likely shift toward personalized medicine. Identifying which patients are most likely to benefit from this intensive, monitored approach will be the next great challenge in psychiatry.
For now, the message from advocates like Dr. Jain is clear: the data compels clinicians to look beyond the status quo. If the current trajectory holds, Spravato will not only continue its commercial success but will fundamentally alter the therapeutic landscape for the most difficult-to-treat cases in psychiatry. The focus on remission, as presented in the latest findings, serves as a rallying cry for a field that has long accepted "improvement" as the best possible outcome for its most vulnerable patients.
About the Author
